Please select the option that best describes you:
Topics:
Neuro-Oncology • Pediatric Hematology/Oncology • Neurology • Journal Club ft. Nature Publications • Low-Grade Glioma
How has the recent FDA approval of tovorafenib impacted your treatment decisions for pediatric patients with relapsed/refractory low-grade glioma?
Is it merely another option to try or will it become the standard choice for patients experiencing relapsed/refractory disease?
Answer from: at Academic Institution
With the FDA approval, and given the tolerability of therapy and the pediatric friendly once weekly dosing and formulations, I will prescribe tovorafenib regularly for my patients with relapsed refractory low grade glioma. I do think it will become a standard choice in this setting. That said, given...
Sign in or Register to read more
Answer from: at Academic Institution
If we look at the current landscape, tovorafenib is - in the USA - the only targeted therapy approved for the second-line treatment of BRAF-altered pLGG. So, this is a great opportunity for patients. There is no MEK inhibitor approved in this setting (trametinib, selumetinib, binimetinib, mirdametin...